Physician

Henry J Kanarek, M.D.

According to 2025 Medicare claims, Henry Kanarek, M.D. (NPI: 1801983408) practices allergy/immunology in the Kansas City, MO-KS market, with the plurality of this provider's patient population coming from Jackson, MO. This provider's primary affiliated billing organization is HENRY J. KANAREK M.D. PA (NPI: 1881781409; TIN: 481243528) and primary practice location at 66211-1349.

Kanarek's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 259 traditional Medicare patients, billed 53,987 HCPCS/CPT codes, and received $2,614,517 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 3,356 prescription claims across 450 beneficiaries totaling $11,477,043 in drug costs, led by Kalbitor (Ecallantide). DME data shows 200 claims. Open Payments data shows 368 records totaling $28,066. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $167,535 to $2,614,517. Similarly, Part D prescription costs have risen steadily, from $434,216 to $11,477,043. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $3,668 to $5,087.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	248	6,418	$167,535
2016	298	12,077	$339,128
2017	308	29,493	$763,993
2018	318	38,701	$1,064,537
2019	309	32,525	$903,721
2020	239	27,463	$754,611
2021	255	26,634	$840,007
2022	250	33,387	$1,296,462
2023	259	44,027	$1,665,694
2024	259	53,987	$2,614,517

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	266	1,883	$434,216
2016	330	2,617	$1,450,437
2017	367	3,211	$9,412,784
2018	382	3,213	$3,585,773
2019	362	3,191	$5,681,349
2020	355	2,967	$8,370,105
2021	357	2,886	$10,532,216
2022	416	3,197	$13,258,903
2023	432	3,211	$12,340,578
2024	450	3,356	$11,477,043

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	27	305	$967,430
2016	27	365	$1,350,726
2017	40	324	$1,099,581
2018	24	361	$990,597
2019	36	375	$777,232
2020	N/R	242	$379,495
2021	N/R	179	$386,261
2022	N/R	290	$489,523
2023	N/R	245	$456,741
2024	N/R	200	$349,624

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	55	55	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	190	400	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	77	157	$66
94010	Test to measure expiratory airflow and volume	70	83	$19
96372	Injection of drug or substance under skin or into muscle	66	648	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kalbitor	Ecallantide	16	249	$3,512,618
Orladeyo	Berotralstat Hydrochloride	76	2,128	$3,170,407
Ruconest	C1 Esterase Inhibitor, Recomb	13	104	$1,608,203
Firazyr	Icatibant Acetate	14	391	$1,258,588
Takhzyro	Lanadelumab-Flyo	16	560	$865,171

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	41	$172,035
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	36	$157,254
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	49	$16,153
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	31	$2,301
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	12	$1,511

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	347	$16,716	Pharming Healthcare, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	21	$11,351	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Henry J. Kanarek, M.D.?

Tedicare shows public-source Medicare data for Henry J. Kanarek, M.D. (NPI 1801983408), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Henry J. Kanarek, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Henry J. Kanarek, M.D.?

Henry J. Kanarek, M.D. is linked to HENRY J. KANAREK M.D. PA (billing NPI 1881781409) in the available physician profile data.

Does Henry J. Kanarek, M.D. have Open Payments data?

Henry J. Kanarek, M.D. has 368 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.